One clinical trial, HVTN 505 (DNA/Ad5), did report a correlation between Env-specific CD8+ T cell magnitude and polyfunctionality and decreased infection risk (hazard ratio = 0.51 and 0.47, respectively) [43,44]. The gene discussed is CD8A; the disease is infection.